These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 25818308)

  • 1. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
    Rioufol C; Salles G
    Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M; Coiffier B; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
    Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
    BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab biosimilars for lymphoma in Europe.
    Jurczak W; Długosz Danecka M; Buske C
    Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
    [No Abstract]   [Full Text] [Related]  

  • 5. CT-P10 (Truxima™): A Rituximab Biosimilar.
    Deeks ED
    BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
    Kim WS; Coiffier B; Kwon HC; Kim S
    Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.
    Coiffier B
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):923-933. PubMed ID: 28766389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
    Buske C; Ogura M; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.
    Cobb P; Niederwieser D; Cohen S; Hamm C; Burmester G; Seo N; Lehto SG; Hanes V
    Immunotherapy; 2022 Jun; 14(9):727-740. PubMed ID: 35543293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ; Klein AV; Wang J
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis.
    Salinas-Jazmín N; González-González E; Vásquez-Bochm LX; Pérez-Tapia SM; Velasco-Velázquez MA
    J Vis Exp; 2017 May; (123):. PubMed ID: 28518088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
    Braun J; Kay J
    Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
    Robak T
    Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.
    Kim WS; Ogura M; Kwon HC; Choi D
    Future Oncol; 2017 May; 13(15s):17-29. PubMed ID: 28482701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.